Results 201 to 210 of about 17,826,638 (304)

Comment on Autoimmune Complications of Lymphoproliferative Diseases. [PDF]

Hematol Oncol
Balaban YA.
europepmc   +1 more source

Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia. [PDF]

Blood Cancer J
Hampel PJ, Huang Y, Allan JN, Bhat SA, Bond D, Brander DM, Byrd JC, Chavez JC, Chong E, Danilov A, Davids MS, Dvorak-Kornaus K, Freedman H, Malakhov N, Matasar M, Miller C, Miller S, Omer Z, Parikh SA, Parry EM, Rabe KG, Raess P, Rai M, Rhodes JM, Rogers KA, Saha A, Schade J, Shouse G, Spurgeon S, Stephens D, Wang Y, Woyach JA, Yano M, Kittai AS.   +33 more
europepmc   +1 more source

Resolution of Paraneoplastic Cutaneous Angioendotheliomatosis After CAR T-Cell Therapy in TP53-Deleted CLL: A Case Report. [PDF]

EJHaem
Alfraih F, Saleh MFM, Li D, Mohty R, Kharfan-Dabaja M.   +4 more
europepmc   +1 more source

Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia. [PDF]

Ann Hematol
Chen B, Qian S.
europepmc   +1 more source

Progressive multifocal leukoencephalopathy in an untreated chronic lymphocytic leukemia patient: Case report and review of the literature. [PDF]

Radiol Case Rep
Khoei S, Marshall M, Basappa E, Gaddikeri S, Jhaveri M.   +4 more
europepmc   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

A case report of CD4^- CD8⁺ CD56^- TCRγδ⁺ T-large granular lymphocytic leukaemia with severe aplastic anemia and a PNH clone. [PDF]

Ann Hematol
Du Y, Zhang J, Jin S.
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Second Primary Malignancies in Patients With B-Cell Lymphomas Treated With Bruton's Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Eur J Haematol
Ma C, Lu Y, Li J, Liu W, Liu J.
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source